LVW Advisors LLC Increases Position in HCA Healthcare, Inc. $HCA

LVW Advisors LLC lifted its position in shares of HCA Healthcare, Inc. (NYSE:HCA) by 21.9% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 3,639 shares of the company’s stock after buying an additional 653 shares during the period. LVW Advisors LLC’s holdings in HCA Healthcare were worth $1,394,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the company. Price T Rowe Associates Inc. MD raised its stake in HCA Healthcare by 83.4% during the first quarter. Price T Rowe Associates Inc. MD now owns 2,399,372 shares of the company’s stock worth $829,104,000 after purchasing an additional 1,091,416 shares during the period. Goldman Sachs Group Inc. raised its stake in HCA Healthcare by 49.1% during the first quarter. Goldman Sachs Group Inc. now owns 1,781,459 shares of the company’s stock worth $615,583,000 after purchasing an additional 587,036 shares during the period. GAMMA Investing LLC raised its stake in HCA Healthcare by 40,527.3% during the first quarter. GAMMA Investing LLC now owns 1,703,907 shares of the company’s stock worth $5,887,850,000 after purchasing an additional 1,699,713 shares during the period. Nuveen LLC purchased a new position in HCA Healthcare during the first quarter worth approximately $569,217,000. Finally, Pacer Advisors Inc. raised its stake in HCA Healthcare by 6,237.9% during the first quarter. Pacer Advisors Inc. now owns 1,350,933 shares of the company’s stock worth $466,815,000 after purchasing an additional 1,329,618 shares during the period. Hedge funds and other institutional investors own 62.73% of the company’s stock.

Insider Buying and Selling

In related news, EVP Michael S. Cuffe sold 3,836 shares of the company’s stock in a transaction on Monday, September 8th. The shares were sold at an average price of $418.84, for a total transaction of $1,606,670.24. Following the completion of the sale, the executive vice president directly owned 31,503 shares of the company’s stock, valued at approximately $13,194,716.52. This represents a 10.85% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.30% of the stock is owned by corporate insiders.

HCA Healthcare Stock Up 1.2%

HCA stock opened at $419.77 on Friday. HCA Healthcare, Inc. has a 52 week low of $289.98 and a 52 week high of $422.46. The company has a market capitalization of $98.22 billion, a price-to-earnings ratio of 17.64, a price-to-earnings-growth ratio of 1.30 and a beta of 1.41. The firm’s 50-day moving average is $389.80 and its two-hundred day moving average is $368.78. The company has a current ratio of 0.98, a quick ratio of 0.86 and a debt-to-equity ratio of 69.07.

HCA Healthcare (NYSE:HCA) last announced its quarterly earnings data on Friday, July 25th. The company reported $6.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.20 by $0.64. The company had revenue of $18.61 billion for the quarter, compared to analysts’ expectations of $18.49 billion. HCA Healthcare had a net margin of 8.21% and a negative return on equity of 7,363.11%. The business’s revenue was up 6.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $5.50 EPS. HCA Healthcare has set its FY 2025 guidance at 25.500-27.000 EPS. On average, analysts forecast that HCA Healthcare, Inc. will post 24.98 earnings per share for the current fiscal year.

HCA Healthcare Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 30th. Shareholders of record on Tuesday, September 16th will be paid a $0.72 dividend. This represents a $2.88 annualized dividend and a yield of 0.7%. The ex-dividend date is Tuesday, September 16th. HCA Healthcare’s dividend payout ratio is currently 12.11%.

Wall Street Analysts Forecast Growth

HCA has been the topic of a number of research reports. Barclays raised their target price on shares of HCA Healthcare from $390.00 to $445.00 and gave the company an “overweight” rating in a research note on Thursday, September 18th. Bank of America raised their target price on shares of HCA Healthcare from $375.00 to $410.00 and gave the company a “neutral” rating in a research note on Wednesday, September 10th. Truist Financial raised their target price on shares of HCA Healthcare from $390.00 to $415.00 and gave the company a “buy” rating in a research note on Wednesday, July 16th. JPMorgan Chase & Co. raised their target price on shares of HCA Healthcare from $360.00 to $370.00 and gave the company a “neutral” rating in a research note on Monday, August 4th. Finally, Wells Fargo & Company lowered their price target on shares of HCA Healthcare from $385.00 to $375.00 and set an “equal weight” rating for the company in a report on Thursday, August 14th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $407.75.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.